Treatment outcomes
Treatment Response May Not Tell the Whole Story in Bladder Cancer
A strong pathological response to neoadjuvant chemotherapy is generally viewed as an encouraging sign in muscle-invasive bladder cancer, but new research suggests that response alone may not fully capture a patient's longer-term outlook. In a retrospective study using a practical immunohistochemistry-based approach to classify bladder tumors, researchers found a notable disconnect between treatment response and survival: non-luminal tumors responded more favorably to neoadjuvant chemotherapy, while patients with luminal tumors experienced better long-term outcomes.
The study included 590 patients with bladder cancer treated at a single center, including 352 with luminal tumors and 238 with non-luminal tumors. Researchers classified tumors using four immunohistochemical markers: CK20, GATA3, CK5/6, and CK14. This approach was designed as a more clinically feasible surrogate for transcriptome-based molecular classification, which can identify biologically distinct bladder cancer subtypes but remains difficult to implement routinely.
Important differences emerged between the two groups. Non-luminal tumors displayed more aggressive pathological characteristics, including greater tumor budding, more frequent non-cohesive or spindle/single-cell growth, and more disseminated patterns of tumor spread. They were also considerably more likely to be muscle invasive: 69.3% of non-luminal tumors were MIBC compared with 37.5% of luminal tumors. Among the 118 patients who received neoadjuvant chemotherapy, however, non-luminal tumors achieved a significantly higher pathological complete response rate than luminal tumors.
The survival results told a different story. Despite their lower pathological response to neoadjuvant chemotherapy, patients with luminal tumors experienced significantly better overall survival, recurrence-free survival, and progression-free survival. After adjustment for other clinical and pathological factors, luminal subtype remained independently associated with a lower risk of death, with a hazard ratio of 0.51 compared with non-luminal disease. Luminal tumors were also associated with lower risks of recurrence and progression.
The findings illustrate why treatment response and underlying tumor biology may provide different pieces of information about bladder cancer prognosis. A tumor may be relatively sensitive to chemotherapy while retaining biological characteristics associated with more aggressive long-term behavior. Although the retrospective, single-center design means the results require further validation, the study suggests that a small immunohistochemical panel could potentially provide additional information about tumor behavior beyond conventional staging and pathological response. Prospective studies will be needed to determine whether this type of molecular classification can ultimately help guide treatment selection or post-treatment surveillance.